Male Health

YourChoice Therapeutics commences male birth control pill trial

YourChoice Therapeutics has commenced the dosing of subjects in a Phase I clinical trial of YCT-529 for its potential as…

Dicot doses first participants in LIB-01 study

Dicot has dosed the first participants in a Phase I clinical trial of LIB-01 to treat erectile dysfunction and premature…

Endurance reports positive data for premature ejaculation spray

Endurance announced that its commercial partner Wanbang Biopharmaceuticals has completed a Phase III study of Fortacin (lidocaine/prilocaine) in China for…

New prostate cancer risk prediction tool identifies men at highest risk

Prostate cancer is the fourth most common cancer worldwide and the most common cancer among men in the UK. In…

Tavanta concludes subject enrolment in Phase III prostate cancer trial

Tavanta Therapeutics has concluded subject enrolment in its pivotal Phase III clinical trial of TAVT-45 (abiraterone acetate) granules for oral…

Increase in prostate cancer screening after rollout of revised national guidelines

In May 2018, the US Preventive Services Task Force (USPSTF) published new prostate cancer screening guidelines, which had last been…

Slow progress for male contraceptive trials

Within the pharmaceutical sphere, it is commonly known that the development of reversible male contraception has been extremely difficult. Options…

Astellas-Pfizer’s Xtandi reduces mortality risk in prostate cancer trial

Astellas Pharma and Pfizer have reported that their drug Xtandi (enzalutamide) enhanced overall survival (OS) in the Phase III ARCHES…

Pfizer initiates dosing in Phase III prostate cancer drug trial

Pfizer has dosed the first subject in a Phase III TALAPRO-3 clinical trial of oral drug talazoparib plus enzalutamide in…

Telix begins Phase III prostate cancer treatment trial

Telix Pharmaceuticals has begun a Phase III ProstACT clinical trial of its therapy candidate, TLX591 (177Lu-DOTA-rosopatamab), in advanced metastatic castrate-resistant…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close